JEFF BROWN RECENT TEASERFOR EXPONENTIAL TECH, regarding a small biotech:
”In July 2018, this biotech announced positive results for its Phase 1 clinical trials. And get this. This drug has been used for many years in Japan with few adverse side effects.
Because of this, the FDA granted the drug a qualified infectious disease product designation. In other words, the FDA allowed the company to skip Phase 2 trials and move directly into Phase 3.”
”It’s 2020… and antibacterial infections are killing people at a rate similar to the Middle Ages.
Yet we’re using antibiotics made in the 1980s to treat them. These antibiotics are terribly ineffective today. Even dangerous to rely on.
The CDC warns that 2.8 million Americans will be affected just this year.
It’s why the FDA fast-tracked the approval of the most powerful antibiotic in nearly 40 years.”
Any idea what company this is?
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
I have been researching this and haven’t gotten terribly far, but thought I would throw this 1 out.
https://www.marketbeat.com/stocks/NASDAQ/SPRO/
Spero therapeutics
I got here because it was listed as a company that Google has invested in.
That was mentioned in Jeff Brown’s audio (that I finally had to stop listening to… LONG, AS USUAL)
the current market Cap: $204 million
I think Jeff indicated it was $180 million
pretty close.
It’s up about 18% today, 4/27.
I still haven’t determined if they have a drug that has skipped phase 2.
Spero (SPRO) does have a pipeline that is focused on multi-drug resistant (MDR) pathogens. They have several trials in progress and recently received orphan drug status for SPR720 which treats nontuberculous myobacterial infections.
They also just appointed Scott Jackson to BoD. He was CEO of Celator Pharm. until it was acquired by Jazz Pharma.
TRAVIS, WHAT ABOUT JEFF HOWARD’S BIOTECH, STAGE 3, OUT OF MASSACHUSETTS – ANY IDEA WHAT IT IS???
I just posted this. (Spero Therapeutics, us military, antibiotic trials) Came up with SPERO ! I BELIEVE THIS MAY BE IT! ABOUT $10
SPRO is up about 20% today. Institutional ownership is ~48%. No insider trades reported since 2018. Insiders own ~18%. This has definitely been a pump today. It will be curious to see if they follow with an offering.
what kind of offering do you suspect?
I was doing some reading earlier. They just closed an offering in Feb. that raised $30M on 1M shares. So I don’t see a new offering so close in timing. They do have a trial in Phase 3 which is due to report in Q3 2020. They also recently received $15M from BARDA for reimbursements due to a milestone achievement. GlaxoSmithKline is an “insider” by virtue of shares held. All of these factors are in line with Jeff Brown’s mystery bio-tech.
Just been looking at Spero, and believe this is likely the subject of the tease. Further, in the Spero website, there is a 2019 news article quoting the founder, who refers to a drug they sourced from Japan, widely administered to children there: SPR994: A Long Shot, With Lots Of Twists And Turns To Phase III
Posted May 23rd, 2019
I’ve been following this discussion. I felt strongly that the dots lined up on SPRO (Spero). Bought it at $12. However, for such an exciting story the stock has been fumbling around – a bit of a gain, a bit of a loss. Really nothing special so far. I think there’s an announcement in July. Hope they have a catalyst to pull them up and out. So far, not much to write home about.
I had sideline money back when I looked at this and purchased for $10.31. It jumped up initially and has remained around the $12 mark ($11.78 as of Friday, 5/8). July 1 was mentioned as potential news, but it’s really Q3 the target for the study news. That said, it may be September. I’m going to be patient, but I’m not certain how patient. It’s 52 week high is a mere $14.38. If it were to move to $13 or above, I will be inclined to “count my lucky stars” and take a fortunate gain and go elsewhere.